SOTIO Biotech announced that it has entered into a clinical trial collaboration and supply agreement with MSD to evaluate the combination of SOT101, SOTIO’s IL-15 superagonist, and MSD’s KEYTRUDA® in patients with selected advanced/refractory solid tumors in the Phase II AURELIO-04 study.
[SOTIO Biotech]
7992332
{7992332:nan}
apa
50
1
169856
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
